The world is waiting eagerly for Covid-19 vaccines to be developed as quickly as possible. But to make sure they are safe and effective, the clinical trials that test them have to be robust. So how do trials achieve this?
Researchers may well identify a safe, effective vaccine for COVID-19 before too long, but all that fantastic work could count for nothing unless we also invest in the next stages of the vaccine process – manufacturing and delivery.
With measures to prevent the spread of COVID-19 disrupting immunisation around the globe, millions are now at risk of other deadly diseases. We must act and invest urgently to maintain routine immunisation.
As COVID-19 continues to spread around the world, a global community of researchers are working to find out more about the virus and assess what research needs to be done to stop it.
Vaccines are one of our most powerful health tools. Here’s some of the lessons we’ve learned about the development and use of vaccines from past outbreaks.
A vaccine for COVID-19 which uses cutting-edge RNA technology has entered phase 1 clinical trials. If successful, it could revolutionise the future of vaccine development.
As the UK begins life after Brexit, Wellcome's Director Jeremy Farrar sets out what the transition period and beyond could mean for research.